Skip to main content
. 2023 Apr 14;25:41. doi: 10.1186/s13058-023-01646-z

Fig. 7.

Fig. 7

The "CLDN4-high/LXRβ-high" TNBC cases exhibit poor prognosis. A Immunohistochemical staining of CLDN4 and LXRβ in breast cancer tissues. Four representative patterns are presented depending on the expression levels of CLDN4 and LXRβ. HE, hematoxylin–eosin. Scale bar, 100 µm. B The overall and recurrence-free survival in "CLDN4-high/LXRβ-high" and "CLDN4-low and/or LXRβ-high" groups of the indicated breast cancer subjects